Affiliations 

  • 1 Institute for Public Health, Ministry of Health, Kuala Lumpur, Malaysia. norasiahdr@gmail.com
  • 2 Family Health Development Division, Ministry of Health, Kuala Lumpur, Malaysia
  • 3 Disease Control Division, Ministry of Health, Kuala Lumpur, Malaysia
  • 4 Faculty of Science and Technology, Open University Malaysia, Kuala Lumpur, Malaysia
  • 5 Institute for Public Health, Ministry of Health, Kuala Lumpur, Malaysia
  • 6 Department of Community Medicine, International Medical University, Kuala Lumpur, Malaysia
  • 7 Office of Deputy Director General of Health (Research and Technical Support), Ministry of Health, Putrajaya, Malaysia
BMC Public Health, 2018 Dec 22;18(1):1402.
PMID: 30577816 DOI: 10.1186/s12889-018-6316-6

Abstract

BACKGROUND: In 2006, 4 years of planning was started by the Ministry of Health, Malaysia (MOH), to implement the HPV (human papillomavirus) vaccination programme. An inter-agency and multi-sectoral collaborations were developed for Malaysia's HPV school-based immunisation programme. It was approved for nationwide school base implementation for 13-year-old girls or first year secondary students in 2010. This paper examines how the various strategies used in the implementation over the last 7 years (2010-2016) that unique to Malaysia were successful in achieving optimal coverage of the target population.

METHODS: Free vaccination was offered to school girls in secondary school (year seven) in Malaysia, which is usually at the age of 13 in the index year. All recipients of the HPV vaccine were identified through school enrolments obtained from education departments from each district in Malaysia. A total of 242,638 girls aged between 12 to 13 years studying in year seven were approached during the launch of the program in 2010. Approximately 230,000 girls in secondary schools were offered HPV vaccine per year by 646 school health teams throughout the country from 2010 to 2016.

RESULTS: Parental consent for their daughters to receive HPV vaccination at school was very high at 96-98% per year of the programme. Of those who provided consent, over 99% received the first dose each year and 98-99% completed the course per year. Estimated population coverage for the full vaccine course, considering also those not in school, is estimated at 83 to 91% per year. Rates of adverse events reports following HPV vaccination were low at around 2 per 100,000 and the majority was injection site reactions.

CONCLUSION: A multisectoral and integrated collaborative structure and process ensured that the Malaysia school-based HPV immunisation programme was successful and sustained through the programme design, planning, implementation and monitoring and evaluation. This is a critical factor contributing to the success and sustainability of the school-based HPV immunisation programme with very high coverage.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.